In this section
@article{Carrithers:2025:10.1016/j.neuropharm.2025.110413,
author = {Carrithers, BM and Roberts, DE and Weiss, BM and King, JD and Carhart-Harris, RL and Gordon, AR and Pagni, BA and Moreau, M and Ross, S and Zeifman, RJ},
doi = {10.1016/j.neuropharm.2025.110413},
journal = {Neuropharmacology},
title = {Exploring serotonergic psychedelics as a treatment for personality disorders.},
url = {http://dx.doi.org/10.1016/j.neuropharm.2025.110413},
volume = {272},
year = {2025}
}
TY - JOUR
AB - Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy could hold potential for addressing core features of PDs through shared mechanisms of personality modulation. Although historical literature and observational studies suggest the potential clinical utility of psychedelics in treating PDs, rigorous research is lacking, and individuals with PDs are often excluded from modern psychedelic therapy trials. In the present review, we first discuss research on the effects of psychedelics in individuals with a PD through the conventional lens of the Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR) categorical model. Next, using the dimensional DSM Alternative Model of Personality Disorders (DSM-AMPD) as a framework, we examine how psychedelics may affect self-functioning, interpersonal functioning, and pathological personality traits. We conclude by discussing the clinical relevance of psychedelic therapy as a treatment for personality pathology, including safety considerations, gaps and limitations, and recommendations for approaching psychedelic therapy within these more complex clinical populations.
AU - Carrithers,BM
AU - Roberts,DE
AU - Weiss,BM
AU - King,JD
AU - Carhart-Harris,RL
AU - Gordon,AR
AU - Pagni,BA
AU - Moreau,M
AU - Ross,S
AU - Zeifman,RJ
DO - 10.1016/j.neuropharm.2025.110413
PY - 2025///
TI - Exploring serotonergic psychedelics as a treatment for personality disorders.
T2 - Neuropharmacology
UR - http://dx.doi.org/10.1016/j.neuropharm.2025.110413
UR - https://www.ncbi.nlm.nih.gov/pubmed/40081794
VL - 272
ER -
